Next Generation Therapeutics for Repair of Human Organs and Tissues – Bioquark [transcript][audio]
Guest: Ira Pastor
Presenter: Neal Howard
Guest Bio: Ira Pastor is the Chief Executive Officer at Bioquark Inc with over 30 years of experience across multiple sectors of the pharmaceutical industry, including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail. He served as VP, Business Development for drug development company Phytomedics Inc., raising $40 million of private equity, consummating over $50 million of licensing deals, and bringing lead drug candidate from discovery stage to Phase III development. Prior to that, employed by SmithKline Beecham Pharmaceuticals working in sales, marketing, and business strategy positions. Mr. Pastor has also served as Vice President of Corporate Development for the pharmacy benefit management company Prescription Delivery Systems (acquired by Cigna Health Insurance); MBA, Temple University; BS, Pharmacy, Rutgers University. He is also a Board Member of RegenerAge SAPI de CV, a clinical company focused on expedited translational therapeutic applications of regenerative and rejuvenative healthcare interventions, the Reanima Project, member of the Executive Council of the World Academy of Medical Science – WAMS and member of the World Economic Forum’s Human Enhancement council.
Segment Overview: Ira S. Pastor discusses Bioquark, Inc, a life sciences company developing proprietary combinatorial biologics for the regeneration and repair of human organs and tissues.
0 Comments